Form: SC 13G/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

February 16, 2021

Documents

 

EXHIBIT 99.1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Sutro Biopharma, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

 

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

 

Dated this 16th day of February, 2021.

 

CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
     
By: /s/ Guy Miller   By: /s/ Gregory Johnson
  Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
     
CALC IV LP   CITADEL ADVISORS HOLDINGS LP
     
By: /s/ Guy Miller   By: /s/ Gregory Johnson
  Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
     
CITADEL SECURITIES GP LLC   CITADEL GP LLC
     
By: /s/ Guy Miller   By: /s/ Gregory Johnson
  Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
     
    KENNETH GRIFFIN
     
    By: /s/ Gregory Johnson
      Gregory Johnson, attorney-in-fact*

 

 

 

* Gregory Johnson is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Jaws Acquisition Corp. on February 1, 2021.